Form 4: Vanda Pharmaceuticals CEO Increases Stake with Open Market Purchases
SEC Form 4 Filing
Mihael Hristos Polymeropoulos, CEO of Vanda Pharmaceuticals, recently acquired 10,000 shares of company stock through open market purchases.
Summary
- Mihael Hristos Polymeropoulos, the President and CEO and Chairman of the Board of Vanda Pharmaceuticals, has reported changes in beneficial ownership of the company's stock.
- On March 5, 2025, Polymeropoulos purchased 5,000 shares of common stock at $5.01 per share and another 5,000 shares at $5.03 per share.
- Following these transactions, Polymeropoulos directly owns 2,285,731 shares of Vanda Pharmaceuticals.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The CEO's purchase of shares is generally seen as a positive sign, but the filing itself is a routine disclosure.
Positives
- The CEO's purchase of shares could be interpreted as a sign of confidence in the company's future prospects.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. These filings are closely watched by investors as they can provide signals about management's view of the company's prospects.
Stakeholder Impact
- Shareholders may view the CEO's stock purchase as a positive signal.
Key Dates
| Date | Description |
|---|---|
| 03/05/2025 | Date of stock purchase transactions. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.